CN111925961A - 一株植物乳杆菌Lp2及其应用 - Google Patents
一株植物乳杆菌Lp2及其应用 Download PDFInfo
- Publication number
- CN111925961A CN111925961A CN202010810884.2A CN202010810884A CN111925961A CN 111925961 A CN111925961 A CN 111925961A CN 202010810884 A CN202010810884 A CN 202010810884A CN 111925961 A CN111925961 A CN 111925961A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- parts
- powder
- freeze
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 80
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 80
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 80
- 239000000843 powder Substances 0.000 claims abstract description 32
- 239000006041 probiotic Substances 0.000 claims abstract description 24
- 235000018291 probiotics Nutrition 0.000 claims abstract description 24
- 230000000529 probiotic effect Effects 0.000 claims abstract description 20
- 244000068988 Glycine max Species 0.000 claims abstract description 15
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 14
- 235000013361 beverage Nutrition 0.000 claims abstract description 13
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000004321 preservation Methods 0.000 claims abstract description 8
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 7
- 239000008369 fruit flavor Substances 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003223 protective agent Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000020183 skimmed milk Nutrition 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 3
- 240000000171 Crataegus monogyna Species 0.000 claims description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 3
- 229920001218 Pullulan Polymers 0.000 claims description 3
- 239000004373 Pullulan Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 3
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000004634 cranberry Nutrition 0.000 claims description 3
- 235000019423 pullulan Nutrition 0.000 claims description 3
- 241001052560 Thallis Species 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 238000011156 evaluation Methods 0.000 abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000006022 acute inflammation Effects 0.000 abstract description 5
- 208000038016 acute inflammation Diseases 0.000 abstract description 5
- 229940099352 cholate Drugs 0.000 abstract description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000006870 function Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 208000004232 Enteritis Diseases 0.000 abstract description 3
- 230000006518 acidic stress Effects 0.000 abstract description 3
- 244000052616 bacterial pathogen Species 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000035882 stress Effects 0.000 abstract description 3
- 230000001580 bacterial effect Effects 0.000 description 24
- 239000002158 endotoxin Substances 0.000 description 23
- 229920006008 lipopolysaccharide Polymers 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 18
- 238000012258 culturing Methods 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 235000021108 sauerkraut Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000006067 antibiotic powder Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005549 barrier dysfunction Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一株植物乳杆菌Lp2,它的保藏编号为CCTCC NO:M 2019935;一种益生菌固体饮料,它包括下列重量份数的组分:植物乳杆菌冻干粉10份,低聚异麦芽糖5~10份,大豆低聚糖5~10份,果味粉5~15份;所述的植物乳杆菌保藏编号为CCTCC NO:M 2019935;所述的一株植物乳杆菌Lp2在制备抗肠炎药物的应用;结果表明,植物乳杆菌Lp2具有良好的耐受酸胁迫、耐受胆盐胁迫、抗致病菌感染、较高的肠道定植能力,对LPS诱导的急性炎症具有保护作用;植物乳杆菌Lp2菌株在体外益生功能评价和小鼠体内的各项指标均优于其他菌株,表明植物乳杆菌Lp2在发挥抗炎方面表现出明显的菌株特异性。
Description
技术领域
本发明属于微生物技术领域,具体涉及一株植物乳杆菌Lp2及其应用。
背景技术
在日常生活中,一些不良的饮食习惯,如高脂和酒精的过量摄入等,会导致体内脂多糖升高。当过量的脂多糖进入血液循环,与宿主接触时,能引发系统性炎症反应,导致多个器官的损伤,休克,甚至死亡。事实上,肥胖,糖尿病,心血管疾病和非酒精性脂肪肝疾病患者表现出血液中LPS水平的上升,这些重大疾病的发生都与炎症相关。研究证实这些疾病患者体内的大多数内毒素不是来源于感染本身,是由胃肠道内的内毒素转移引起。
革兰氏阴性菌产生的脂多糖(LPS)能直接激活哺乳动物的单核巨噬细胞产生大量炎症介质,如肿瘤坏死因子-α (TNF-α)等,这些炎症介质能直接或间接地对细胞和组织产生损伤作用。在一些炎症机体内,肠道菌群紊乱和屏障功能失调的情况普遍存在,由此导致肠道来源的LPS移位进入肝脏等器官,进一步恶化脏器功能。
益生菌是一类能对机体产生有益作用的微生态制剂。益生菌作用于胃肠道具有改善肠道菌群、提高免疫、抗过敏、抗氧化、抗炎、降胆固醇、降压、减肥等功效。近年来研究发现一些乳酸菌发挥这些功效的作用机制主要包括:改善肠道粘膜屏障功能;增强免疫调节功能;修复机体氧化损伤、提高抗氧化能力等,在一些与LPS相关,并存在肠道屏障功能失调的试验小鼠模型中,益生菌被报道能抑制炎症反应。
目前,对于炎症性疾病的治疗手段还很局限,主要是临床上使用药物治疗的方法,但药物治疗会带来药物残留以及药物副作用等危害,益生菌作为一种辅助治疗的有效方式,而且与药物治疗相比较价格低廉、安全性高,具有极大的开发前景。
由于我国居民的饮食习惯及遗传因素等与国外人种存在差异,从国外引入的益生菌菌株可能不一定完全适合我国居民服用。我国长白山地区优越的地理环境造就了东北丰富的资源,形成了极具特色的发酵食品,例如东北酸菜、泡菜等,经过长期的自然驯化,乳酸菌形成优势菌株,也是益生菌的良好来源。目前,我国暂无自主知识产权的抗炎作用益生菌菌株或相关产品,因此从我国居民经常食用的自然发酵食品中经平板划线法分离纯化出植物乳杆菌Lp2并研究其抗炎效果,从而开发具有自主知识产权的、适合我国居民服用的益生菌菌株及其制品,对推进我国益生菌产业发展及促进国民身体健康具有重要意义。
发明内容
本发明目的是提供一种具有高肠道定植能力和抗炎作用的植物乳杆菌Lp2及应用。
一株植物乳杆菌Lp2,它的保藏编号为CCTCC NO:M 2019935。
一种益生菌固体饮料,它包括下列重量份数的组分:植物乳杆菌冻干粉10份,低聚异麦芽糖5~10份,大豆低聚糖5~10份,果味粉5~15份;所述的植物乳杆菌,它的保藏编号为CCTCC NO:M 2019935;
所述的果味粉为蓝莓粉、蔓越莓粉或山楂粉;
所述的植物乳杆菌冻干粉,是由下述方法制备的:将植物乳杆菌Lp2活化,扩大培养,在3000~5000r/min下离心8~15min、洗涤,离心弃上清,得到菌体;将菌体和冻干保护剂按体积比1~3:1混合,冷冻干燥,得到植物乳杆菌冻干粉;
所述的冻干保护剂,按质量百分比计算包括下列组分:脱脂奶粉10%-12%、纤维素7%-9%、海藻糖3%-5%、普兰多糖6%-8%,余量为水。
所述的一株植物乳杆菌Lp2在制备抗肠炎药物的应用。
本发明提供了一株植物乳杆菌Lp2,它的保藏编号为CCTCC NO:M 2019935;一种益生菌固体饮料,它包括下列重量份数的组分:植物乳杆菌冻干粉10份,低聚异麦芽糖5~10份,大豆低聚糖5~10份,果味粉5~15份;所述的植物乳杆菌,它的保藏编号为CCTCC NO:M2019935;所述的一株植物乳杆菌Lp2在制备抗肠炎药物的应用;结果表明,植物乳杆菌Lp2具有良好的耐受酸胁迫、耐受胆盐胁迫、抗致病菌感染、较高的肠道定植能力,对LPS诱导的急性炎症具有保护作用;植物乳杆菌Lp2菌株在体外益生功能评价和小鼠体内的各项指标均优于其他菌株,表明植物乳杆菌Lp2在发挥抗炎方面表现出明显的菌株特异性。
附图说明
图1 植物乳杆菌Lp2光学显微镜下的照片;
图2 菌株的16S rRNA基因序列测定结果;(A)16srDNA测序结果,(B)系统发育树;
图3 菌株的生长曲线和产酸能力结果;
图4 菌株对低聚异麦芽糖耐受能力结果;
图5 小鼠的脏器系数测定结果;A:肝脏系数;B: 胸腺系数;C: 脾脏系数;
图6 小鼠血清和肝脏的AST测定结果;A:血清;B:肝脏;
图7 小鼠血清和肝脏的ALT测定结果;A:血清;B:肝脏;
图8 小鼠血清和肝脏的TNF-α测定结果;A:血清;B:肝脏。
具体实施方式
实施例1 植物乳杆菌Lp2的筛选和鉴定
1、菌株的筛选
将市售东北酸菜,在实验室进行乳酸菌分离;将酸菜发酵液以10-1的梯度稀释,涂布于MRS琼脂平板上,厌氧培养24 h,挑取单菌落,在平板上划线分离,反复进行纯化培养,用革兰氏染色法观察菌落形态挑选革兰氏阳性菌株;将挑选的多株菌株,再在液体MRS培养基中37℃培养24h,按照培养液3%的接种量进行接菌,连续活化传代三次,以保证菌体旺盛的生长活力。
所述的液体MRS培养基含有蛋白胨10.0g,牛肉膏 10.0 g,酵母膏 5.0 g,柠檬酸氢二铵[(NH4)2HC6H5O7] 2.0 g,葡萄糖(C6H12O6·H2O) 20.0 g,吐温80 1.0 mL,乙酸钠(CH3COONa·3H2O)5.0 g,磷酸氢二钾(K2HPO4·3H2O) 2.0 g,硫酸镁(MgSO4·7H2O) 0.58g,硫酸锰(MnSO4·H2O)0.25 g。
2、菌悬液的制备
将上述活化并扩大培养的菌液4000 r/min离心10 min,用0.85%的生理盐水洗涤2遍,离心弃上清,得到菌体沉淀,悬浮于等体积的生理盐水中,得到菌悬液。
3、菌种鉴定
将经平板划线法分离出的生长活力较好的革兰氏阳性菌株送到上海生工公司进行测序,经过16SrDNA鉴定;结果为,与植物乳杆菌显示出最高的分子系统学上的亲缘关系(图1);因此命名为植物乳杆菌Lp2,拉丁文学名Lactobacillus plantarum Lp2,现保存于武汉市中国典型培养物保藏中心(中国武汉大学),保藏时间为2019年11月15日,编号:CCTCCNO:M 2019935。
实施例2 植物乳杆菌Lp2耐受性试验
1、植物乳杆菌Lp2生长曲线和产酸能力的测定
植物乳杆菌Lp2在培养过程中,每2 h一次取样,对培养液进行以下分析:总菌数用分光光度法(波长600 nm)测吸光度值(OD);pH值用酸度计测定。该菌株生长曲线和pH值曲线见图3;由图3可知,0~2 h为该菌株的迟滞期,菌株的数目和pH值无变化,2 h后进入对数期,菌数目呈直线快速增长,随着菌数的增多,产代谢物乳酸也越多,pH值随之迅速下降;当pH值降低至2左右时,乳酸菌的生长由于酸抑制而停滞,在18 h后逐渐稳定,到达稳定期。
2、耐酸性评价
分别将菌株(植物乳杆菌Lp2、植物乳杆菌Lp3、短乳杆菌Lb1)按照2%接种量接种于液体MRS培养基,在37℃培养18h;培养液于4℃在4000 rpm离心10 min,得到菌泥用0.85%的生理盐水洗涤两次,用无菌生理盐水将菌泥悬浮,保证活化的菌株约为108 CFU/mL,然后按照2%的接种量将菌悬液接种于pH为2.0,3.0的MRS培养基中,分别在0 h、2 h、4 h取样,用生理盐水进行10倍稀释,稀释适当浓度后涂布于MRS固体培养基中,37℃恒温培养48 h,菌落记数,每个浓度作三个平行,求其平均值,计算活菌数;
结果见表1,从表中看出在低pH条件下,植物乳杆菌Lp2菌株的存活率仍能达到90%以上,说明其具有良好的耐酸能力。
3、耐胆盐评价
将筛选菌株植物乳杆菌Lp2和植物乳杆菌Lp3、短乳杆菌Lb1对比,分别以2%接种量接种于胆盐浓度分别为0.2%,0.3%,0.5%的MRS培养基中,37℃恒温培养,采用平板计数法,进行稀释涂布,每个浓度作三个平行,求其平均值,计算活菌数;结果见表2,从表中看出随着胆盐浓度的升高,植物乳杆菌Lp2菌株活菌数增加,存活率能达到90%以上,说明其具有良好的耐胆盐能力。
4、代谢产物抑菌性评价
利用滤纸片法进行菌株代谢产物的抑菌实验。将活化好的大肠杆菌、金黄色葡萄球菌和沙门氏菌菌液稀释至105 CFU/mL,取0.1 mL涂布到LB平板上,将已灭菌的滤纸片放于平板中,平行放置三个,取已活化好的筛选菌株发酵上清液,分别吸取0.3 mL放入滤纸片上,然后将平板静止20 min后慢慢放于37℃恒温培养箱,培养24 h,观察并测量抑菌圈直径大小,平行实验三次;
结果见表3,从表中看出植物乳杆菌Lp2对大肠杆菌、金黄色葡萄球菌、沙门氏菌的抑菌直径分别为22.90 mm、17.43 mm、30.07 mm,表明其良好的抑菌特性。
5、耐药性评价
将筛选菌株按2%的接种量接入MRS液体培养基,37℃培养至对数生长期,无菌吸取0.1mL至MRS琼脂平板,涂布均匀,选取5种常用的药敏纸片:红霉素、卡那霉素、氯霉素、链霉素、四环素,无菌镊子夹取放至已涂布菌液的MRS平板上,每个平板放置3种不同药敏纸片,37℃培养24 h, 并用游标卡尺准确称量抑制圈直径。
结果见表4,从表中看出植物乳杆菌Lp2对链霉素和卡那霉素不敏感,氯霉素、红霉素、四环素敏感,但仍在安全浓度的范围内。
将筛选菌株以2%接种量接种于256 μg/mL,128 μg/mL,64 μg/mL,32 μg/mL,16 μg/mL,8 μg/mL,4μg/mL,2μg/mL,1μg/mL浓度抗生素的MRS液体培养基中(抗生素粉购自北京Sorlabio公司),与等量MRS正常培养基对照相比,观察筛选菌株对抗生素最低浓度耐受能力。
结果见表5,筛选菌株对卡那霉素和链霉素的最低抑制浓度分别为256和128 μg/mL,对氯霉素和四环素较敏感,最低抑制浓度分别为4和8 μg/mL,对青霉素耐受能力极其敏感。
6、植物乳杆菌Lp2的低聚异麦芽糖耐受能力
将筛选菌株以2%接种量接种于添加低聚异麦芽糖的MRS培养基中,37℃恒温培养,每2h取样测定其OD600(nm)值,绘制生长曲线,做三组平行,观察低聚异麦芽糖对Lp2菌株生长的影响。
培养基配方:蛋白胨 10.0 g,牛肉膏10.0g,酵母膏5.0g,柠檬酸氢二铵[(NH4)2HC6H5O7] 2.0g,低聚异麦芽糖20.0g,吐温80 1.0mL,乙酸钠(CH3COONa·3H2O) 5.0g,磷酸氢二钾(K2HPO4·3H2O) 2.0g,硫酸镁(MgSO4·7H2O) 0.58g,硫酸锰(MnSO4·H2O) 0.25g。
结果见图4,从图中看出随着培养时间增加,菌株OD值增加,说明其具有良好的耐受能力,与正常MRS培养基比较且具有增殖菌株生长能力。
7、植物乳杆菌Lp2对模拟人工胃肠液耐受能力
将筛选菌株按2%的接种量接入到MRS液体培养基,37℃培养24 h,取10 mL菌液在3000g条件下离心10 min下,弃上清,用无菌PBS溶液洗涤两次,收集菌体沉淀加入10mL PBS混匀,取1 mL菌液加入9mL模拟人工胃液(购自 Beijing Biotechnology Co.,Ltd),37℃培养4 h后,再从模拟胃液中取1 mL菌液加入9mL模拟人工肠液(购自 Beijing BiotechnologyCo.,Ltd),37℃培养4h。每2h分别取样平板涂布计数;
结果见表6,从表中看出植物乳杆菌Lp2依次经过pH2.0人工胃液环境中细菌存活力上升,培养4h活菌数略微降低但影响不大,经pH 8.0人工肠液环境后细菌存活率显著增加,可以说明该菌株具有良好的适应体内胃肠液环境的能力。
实施例3. 植物乳杆菌Lp-2对Caco-2 细胞粘附能力试验
1、Caco-2 细胞的培养
将Caco-2细胞接种到细胞培养瓶中,使用含有10%胎牛血清+1%青霉素-链霉素双抗液的DMEM (Dulbecco's modified eagle medium)培养基于37℃、5% CO2条件下培养5~6d细胞聚合度可达到90%~100%;将生长状态良好的Caco-2细胞接种于24孔板上(孔径16 mm,有效膜面积1.9 cm2),接种密度为0.5×105/孔,37℃、5% CO2条件下培养21 d,隔天换液,倒置显微镜下观察细胞生长情况约21 d后细胞形成紧密单层。
2、植物乳杆菌Lp2菌悬液的制备
菌株按2%的接种量接入到MRS液体培养基,37℃培养24 h,然后在3000 g条件下离心5min下,弃上清,收集菌体沉淀于(不含青霉素和链霉素)DMEM溶液中,并调整菌体浓度至109CFU/mL,待用;
3、涂板计数法
培养至21 d的Caco-2细胞,小心吸去24孔板中的培养液,用无菌PBS溶液洗涤两次,每孔加入1 mL制备好的菌悬液或等量DMEM溶液作为空白对照,37℃、5% CO2条件下共孵育2h。2 h后吸走培养液,并用PBS溶液洗两次,以除去过量的未黏附于细胞的植物乳杆菌Lp2。每孔加入0.5 mL胰酶消化1~2 min,再加入0.5 mL DEME培养基并用移液枪小心吹打均匀,取0.1 mL菌悬液连续稀释到合适的浓度梯度,涂布于MRS琼脂培养基,37℃培养24 h,采用平板计数计算结果。黏附率按如下公式计算:
结果表明植物乳杆菌Lp2对Caco-2细胞的黏附率为30.56%,具有较好的黏附肠道细胞的能力,有利于植物乳杆菌Lp2在肠道的定植。
实施例4 动物试验
1、动物的选择
选择健康成年的雄性昆明小鼠30只,将小鼠随机分配为3组,每组10只,饲喂不同饮食,分别为:
A组:正常对照组(Control):普通饲料;
B组:模型对照组(LPS):普通饲料+注射脂多糖;
C组:干预组(Lp2+LPS);普通饲料+注射脂多糖+植物乳杆菌Lp2菌液;
小鼠造模前各组给予基础饲料适应性喂养1周,待其代谢状态稳定后随机分三组,给予普通饲料和饮用水,其中一组额外摄入1mL/天的植物乳杆菌Lp2菌液进行喂养,作为干预组,其他两组作为正常对照组和模型对照组,每10只分笼。每天光照时间12 h,温度控制在20±2℃,湿度50±5%。在小鼠喂养四周后,对模型对照组和Lp2+LPS组腹腔注射脂多糖LPS,正常对照组注射等量的无菌生理盐水,6 h后眼球取血处死。处死前进行称重,麻醉后打开小鼠腹腔和胸腔,立即分离肝脏、脾、肾和盲肠,分别称重。
脏器指数(mg/g)=各脏器重量/小鼠处死前的最终体重。
2、小鼠样本的制备
血液样本制备:将小鼠血液收集在1.5 mL离心管内,常温静置一段时间后低温(4℃)离心,条件为3000 rpm离心10 min,取上清液置于干净离心管中,保存于-80℃,待用。
肝匀浆液的制备:准确称取0.1g小鼠肝脏组织置于1.5 mL离心管中,用手术剪在离心管内剪碎,并加入900 μL生理盐水缓冲液将肝脏组织进行充分匀浆。匀浆结束后,置于冷冻高速离心机内,在4℃条件下离心10 min,转速为3000 rpm,取上清液即得肝脏组织匀浆液,置于-80℃冰箱保存,待用。
3、生化指标的检测
小鼠血清及肝脏中丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)等指标均严格按照试剂盒说明书进行操作;TNF-α用ELISA方法进行检测。
结果及分析:试验结果显示,与模型对照组相比,正常对照组与干预组小鼠肝脏重量均显著低于模型对照组,表明肝脏的病理症状得到了缓解;与模型对照组相比,正常对照组的胸腺系数显著降低,说明LPS诱导的炎症反应对胸腺有很大影响,干预组显著升高,伴随LPS急性炎症的发生免疫器官胸腺的也产生急性反应;与模型对照组相比,正常对照组的脾脏系数显著降低,说明LPS诱导的炎症反应对脾脏有一定的影响,但植物乳杆菌Lp2干预后的LPS小鼠脾脏系数并没有明显变化,说明植物乳杆菌Lp2对LPS诱导过炎症反应的免疫器官脾脏影响不大,但免疫器官胸腺对急性炎症反应影响较大,且差异性显著。实验组血清中与肝脏中AST与ALT的表达量也都显著降低,植物乳杆菌Lp2有效的抑制了血清和肝脏中AST和ALT表达量的升高,分别降低了11.69%、18.92%和13.66%、6.55%,说明植物乳杆菌Lp2对急性肝损伤和急性炎症反应有一定的缓解和改善作用。血清和肝脏中TNF-α表达量存在差异,与模型组相比,肝脏中TNF-α的表达量显著降低,血清中的TNF-α的表达量几乎没有变化。
综上结果表明,植物乳杆菌Lp2同时具有良好的耐受酸胁迫、耐受胆盐胁迫、抗致病菌感染、较高的肠道定植能力,同时,作为具有益生潜能的乳酸菌对LPS诱导的急性炎症具有保护作用;同时,比较了分离自东北酸菜样品的多株乳酸菌,植物乳杆菌Lp2菌株在体外益生功能评价和小鼠体内的各项指标均优于其他菌株,表明植物乳杆菌Lp2在发挥抗炎方面表现出明显的菌株特异性。
实施例5 益生菌食品的制备
1、益生菌发酵豆乳
(1)豆乳的制备:挑选颗粒饱满的大豆,按照大豆:纯水=1:12 加水浸泡8 h。用豆浆机在8000 r/min,1 min的条件下进行磨浆,磨浆过滤之后进行煮浆,100℃ 温度下煮沸 5min,使用150目滤布滤去豆渣;完成豆乳的制备,冷却待用;
(2)菌株的活化:将植物乳杆菌Lp2和嗜热链球菌的冻干菌粉接种于无菌脱脂乳培养基中,分别按最适温度进行培养,充分凝乳后进行传代,传代2~3次,每次接种量3%,活菌数达到109CFU/mL以上;
(3)发酵豆乳的制备:分别将植物乳杆菌Lp2和嗜热链球菌按1:1的比例混合菌株,按照3%-5%的接种量接种至已经冷却好的豆乳中,混合均匀,在 37℃ 条件下发酵4 h后凝乳,放入4℃保存;
2、植物乳杆菌冻干粉
(1)植物乳杆菌Lp2菌体制备:将植物乳杆菌Lp2在37℃条件下培养18 h,按照培养液3%的量进行接种,连续活化三代;将上述活化并扩大培养的种子液4000 r/min离心10 min,用无菌水洗涤2遍,离心后,弃上清,得到菌体沉淀,悬浮于等体积的冻干保护剂中,得到1010CFU/mL的菌悬液;
(2)保护剂制备:在水溶液中分别添加脱脂奶粉10%-12%,纤维素7%-9%,海藻糖3%-5%,普兰多糖6%-8%,在80℃,20 min的条件下灭菌,制成冻干保护剂;
(3)冷冻干燥制备植物乳杆菌冻干粉;
3、益生菌固体饮料
系列益生菌固体饮料(3g)配方:
1)蓝莓风味固体饮料:植物乳杆菌冻干粉1 g,低聚异麦芽糖0.5~1.0 g,大豆低聚糖0.5~1.0 g,蓝莓粉0.5~1.5 g;
2)蔓越莓风味固体饮料:植物乳杆菌冻干粉1 g,低聚异麦芽糖0.5~1.0 g,大豆低聚糖0.5~1.0g,蔓越莓粉0.5~1.5 g;
3)山楂风味固体饮料:植物乳杆菌冻干粉1 g,低聚异麦芽糖0.5~1.0 g,大豆低聚糖0.5~1.0 g,山楂粉0.5~1.5 g;
4)产品规格:上述的几种固体饮料,均采用3 g为1包,添加的植物乳杆菌Lp2的活菌数为1010 CFU/mL。
Claims (6)
1. 一株植物乳杆菌Lp2,它的保藏编号为CCTCC NO:M 2019935。
2.一种益生菌固体饮料,它包括下列重量份数的组分:植物乳杆菌冻干粉5-10份,低聚异麦芽糖5~10份,大豆低聚糖5~10份,果味粉5~15份;所述的植物乳杆菌,它的保藏编号为CCTCC NO:M 2019935。
3.根据权利要求2所述的一种益生菌固体饮料,其特征在于:所述的果味粉为蓝莓粉、蔓越莓粉或山楂粉。
4.根据权利要求3所述的一种益生菌固体饮料,其特征在于:所述的植物乳杆菌冻干粉,是由下述方法制备的:将植物乳杆菌Lp2活化,扩大培养,在3000~5000r/min下离心8~15min、洗涤,离心弃上清,得到菌体;将菌体和冻干保护剂按体积比1~3:1混合,冷冻干燥,得到植物乳杆菌冻干粉。
5.根据权利要求4所述的一种益生菌固体饮料,其特征在于:所述的冻干保护剂,按质量百分比计包括下列组分:脱脂奶粉10%-12%、纤维素7%-9%、海藻糖3%-5%、普兰多糖6%-8%,余量为水。
6.权利要求1所述的一株植物乳杆菌Lp2在制备抗肠炎药物的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810884.2A CN111925961B (zh) | 2020-08-13 | 2020-08-13 | 一株植物乳杆菌Lp2及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810884.2A CN111925961B (zh) | 2020-08-13 | 2020-08-13 | 一株植物乳杆菌Lp2及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111925961A true CN111925961A (zh) | 2020-11-13 |
CN111925961B CN111925961B (zh) | 2022-07-22 |
Family
ID=73311631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010810884.2A Active CN111925961B (zh) | 2020-08-13 | 2020-08-13 | 一株植物乳杆菌Lp2及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111925961B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112111430A (zh) * | 2020-09-27 | 2020-12-22 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
CN115044498A (zh) * | 2022-05-13 | 2022-09-13 | 江南大学 | 一株适于发酵红枣饮料的植物乳杆菌株及其应用 |
CN115418332A (zh) * | 2022-09-02 | 2022-12-02 | 重庆第二师范学院 | 一种具有预防和改善化学性肝损伤的植物乳杆菌 |
CN115838650A (zh) * | 2022-05-06 | 2023-03-24 | 佛山市孛特碧欧微生物科技有限公司 | 植物乳杆菌及其应用 |
CN116004475A (zh) * | 2023-02-15 | 2023-04-25 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN116731939A (zh) * | 2023-08-15 | 2023-09-12 | 山东利邦牧业股份有限公司 | 一种植物乳杆菌及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102115721A (zh) * | 2008-05-08 | 2011-07-06 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
CN102533618A (zh) * | 2012-02-28 | 2012-07-04 | 江南大学 | 一种植物乳杆菌ccfm8724及其用途 |
CN106074623A (zh) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | 植物乳杆菌在制备具有保肝护肝功能的产品中的应用 |
WO2017139697A1 (en) * | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
TWI600758B (zh) * | 2016-09-02 | 2017-10-01 | 嘉藥學校財團法人嘉南藥理大學 | 具免疫調節機能的植物乳桿菌及其用途 |
EP3351617A1 (en) * | 2015-09-15 | 2018-07-25 | University - Industry Cooperation Group of Kyung Hee University | Novel lactobacillus having various functions, and use thereof |
KR102021883B1 (ko) * | 2018-09-07 | 2019-09-17 | 재단법인 전남생물산업진흥원 | 락토바실러스 퍼멘텀 lm1016 균주 및 이를 포함하는 염증 질환 또는 대사 질환의 예방 또는 치료용 조성물 |
CN110272842A (zh) * | 2019-06-25 | 2019-09-24 | 吉林农业大学 | 一株具有减肥降脂功能的植物乳杆菌lp104 |
CN112877262A (zh) * | 2021-04-02 | 2021-06-01 | 天益健康科学研究院(镇江)有限公司 | 一种植物乳杆菌及其应用 |
CN114317353A (zh) * | 2021-12-30 | 2022-04-12 | 浙江大学 | 一种植物乳杆菌zjufyj7及其应用 |
-
2020
- 2020-08-13 CN CN202010810884.2A patent/CN111925961B/zh active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102115721A (zh) * | 2008-05-08 | 2011-07-06 | 景岳生物科技股份有限公司 | 具有抗炎活性的乳杆菌分离株及其用途 |
CN102533618A (zh) * | 2012-02-28 | 2012-07-04 | 江南大学 | 一种植物乳杆菌ccfm8724及其用途 |
EP3351617A1 (en) * | 2015-09-15 | 2018-07-25 | University - Industry Cooperation Group of Kyung Hee University | Novel lactobacillus having various functions, and use thereof |
JP2018536385A (ja) * | 2015-09-15 | 2018-12-13 | ユニバーシティ−インダストリー コーオペレイション グループ オブ キョンヒ ユニバーシティUniversity−Industry Cooperation Group Of Kyung Hee University | 多様な機能性を有する新規乳酸菌およびその用途 |
WO2017139697A1 (en) * | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
CN106074623A (zh) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | 植物乳杆菌在制备具有保肝护肝功能的产品中的应用 |
TWI600758B (zh) * | 2016-09-02 | 2017-10-01 | 嘉藥學校財團法人嘉南藥理大學 | 具免疫調節機能的植物乳桿菌及其用途 |
KR102021883B1 (ko) * | 2018-09-07 | 2019-09-17 | 재단법인 전남생물산업진흥원 | 락토바실러스 퍼멘텀 lm1016 균주 및 이를 포함하는 염증 질환 또는 대사 질환의 예방 또는 치료용 조성물 |
CN110272842A (zh) * | 2019-06-25 | 2019-09-24 | 吉林农业大学 | 一株具有减肥降脂功能的植物乳杆菌lp104 |
CN112877262A (zh) * | 2021-04-02 | 2021-06-01 | 天益健康科学研究院(镇江)有限公司 | 一种植物乳杆菌及其应用 |
CN114317353A (zh) * | 2021-12-30 | 2022-04-12 | 浙江大学 | 一种植物乳杆菌zjufyj7及其应用 |
Non-Patent Citations (8)
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112111430A (zh) * | 2020-09-27 | 2020-12-22 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
CN112111430B (zh) * | 2020-09-27 | 2022-10-21 | 吉林农业大学 | 一种抗氧化与抗衰老双效益生菌及其应用 |
CN115838650A (zh) * | 2022-05-06 | 2023-03-24 | 佛山市孛特碧欧微生物科技有限公司 | 植物乳杆菌及其应用 |
CN115044498A (zh) * | 2022-05-13 | 2022-09-13 | 江南大学 | 一株适于发酵红枣饮料的植物乳杆菌株及其应用 |
CN115044498B (zh) * | 2022-05-13 | 2023-10-03 | 江南大学 | 一株适于发酵红枣饮料的植物乳杆菌株及其应用 |
CN115418332A (zh) * | 2022-09-02 | 2022-12-02 | 重庆第二师范学院 | 一种具有预防和改善化学性肝损伤的植物乳杆菌 |
CN116004475A (zh) * | 2023-02-15 | 2023-04-25 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN116004475B (zh) * | 2023-02-15 | 2024-05-03 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN116731939A (zh) * | 2023-08-15 | 2023-09-12 | 山东利邦牧业股份有限公司 | 一种植物乳杆菌及其应用 |
CN116731939B (zh) * | 2023-08-15 | 2023-11-07 | 山东利邦牧业股份有限公司 | 一种植物乳杆菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111925961B (zh) | 2022-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111925961B (zh) | 一株植物乳杆菌Lp2及其应用 | |
CN110272842B (zh) | 一株具有减肥降脂功能的植物乳杆菌lp104 | |
CN110218681B (zh) | 一株发酵乳杆菌kp101及其应用 | |
CN105132318B (zh) | 植物乳杆菌Grx16及其应用 | |
CN102533588B (zh) | 一株产胞外多糖的短乳杆菌及其应用 | |
CN110317757B (zh) | 一株具降胆固醇及富硒作用的植物乳杆菌hj-s2及其应用 | |
CN108486000B (zh) | 一种双歧杆菌单菌发酵乳制备方法及其应用 | |
CN110577912B (zh) | 一种格氏乳杆菌及其在制备发酵乳中的应用 | |
CN116024130B (zh) | 一株降血尿酸发酵乳杆菌a21215及其应用 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN108707565B (zh) | 一种两歧双歧杆菌及其应用 | |
CN112625979B (zh) | 一种对抗幽门螺杆菌的干酪乳杆菌及其应用 | |
CN111269850B (zh) | 一株具有高黏附能力及降血脂功效的戊糖片球菌pp04 | |
CN110157645B (zh) | 一种唾液乳杆菌y4及其应用 | |
CN114642686B (zh) | 一种复合益生菌及其延缓衰老和抗氧化的作用 | |
CN114574406B (zh) | 鼠李糖乳杆菌菌株wka55及其在制备防治酒精性肝损伤制品方面的用途与产品 | |
CN112812999B (zh) | 一株对阴沟肠杆菌具有抑制作用的植物乳杆菌slb01及其衍生产品和应用 | |
CN104430847A (zh) | 发酵乳杆菌Lactobacillus fermentum Lee工作发酵剂制品及其预防便秘保健用途 | |
CN116144541B (zh) | 一种具有降甘油三酯、降胆固醇、减脂的植物乳杆菌菌株及其应用 | |
CN108018248B (zh) | 一种具有调节抗生素引起的菌群结构紊乱的干酪乳杆菌 | |
CN114752529A (zh) | 植物乳杆菌hom3201菌株及其活菌制剂、制备方法和用途 | |
CN116970539B (zh) | 一种鼠联合乳杆菌、其组合物及用途 | |
CN105505815B (zh) | 一株抗衰老功能的粘膜乳杆菌 | |
CN116814501B (zh) | 一种缓解肥胖的长双歧杆菌长亚种及其应用 | |
US20210069265A1 (en) | Pediococcus Pentosaceus CCFM1012 and Application thereof to Preparation of Campylobacter Jejuni Infection Antagonism Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |